ArticleCureus2024
Factors Associated With "Sterile Cystic Formation" Following the Application of BioGlue® in Brain Surgery and Review of Literature.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction BioGlue® (CryoLife, Inc, Kennesaw, GA), despite being claimed to be a safe and harmless sealant, reportedly has several adverse effects including surgical wound dehiscence. This study aimed to examine the factors that may contribute to this unfavorable outcome in cranial surgery. Methods A retrospective cross-sectional analysis was conducted on patients who underwent brain surgery with the use of BioGlue® between January 2015 and December 2022. One hundred and two individuals were enrolled and classified into two categories based on the incidence of surgical wound complications. The patients' demography, operative details, and the nature of their surgical wound problems were evaluated. Results Out of 102 individuals, 15 experienced postoperative wound complications. Fluid resembling pus was noted; however, laboratory cultures yielded negative results. Complications were significantly more prevalent (seven times higher) among individuals utilizing BioGlue® in proximity to titanium plates for skull defect correction. Patients using the 5 mL pre-filled BioGlue® device had a 2.8 times higher likelihood of complications than the 2 mL version. Using the patient's cranial bone as a barrier during surgery reduced the risk of complications. Conclusions Neurosurgeons should note possible adverse reactions of using a sealant for cranial surgery that include inflammation and wound separation. Treatment should include thorough cleansing and complete removal of BioGlue®. Two prevalent risk factors were the close proximity (direct contact) of BioGlue® to the adjacent titanium plate used for covering skull defect and the volume of sealant used (5 mL or 2 mL).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.